• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Science: A Fortnightly Journal of Research >Clinical effectiveness of preoperative neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: an updated meta-analysis
【24h】

Clinical effectiveness of preoperative neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: an updated meta-analysis

机译：术前新辅助化疗治疗交界性可切除胰腺癌的临床疗效：最新荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The benefit of preoperative neoadjuvant chemotherapy (CT) to borderline resectable pancreatic cancer (BRPC) is still not well known. This study aims to define the benefits of neoadjuvant CT for BRPC patients. By searching databases (PubMed, Embase, Cochrane Library) from 1966 to 2015, all prospective studies were analysed, where preoperative neoadjuvant CT or chemoradiotherapy was given to patients with BRPC. Laparotomy and resection rates were the primary outcomes. Secondary outcome was therapy-induced toxicity, tumour response, and overall survival. Data were shown as weighted frequency with 95% confidence interval. Fifteen studies with a total of 356 patients were included. All patients had BRPC and received neoadjuvant CT. Following the preoperative therapy, 78.1% of evaluable patients underwent laparotomy and 76.3% of laparotomy patients were performed resection. Also, 86% of specimens were deemed microscopically negative (R0) resection margins. At restaging following treatment, weighted frequencies for complete/partial response were 23.0%, 54.3% for stable disease, 23.4% for progressive disease and 23.6% for treatment-related grade 3-4 toxicity. The mean of overall survial amounted to 21.8 months for the resected patients, and 11.6 months for the unresected ones. This meta-analysis indicates that a benefit of preoperative neoadjuvant CT could be to spare surgery to BRPC patients with progressive disease during CT is administrated. But downstaging of the lesion following treatment is uncommon.
机译：术前新辅助化疗（CT）对交界性可切除胰腺癌（BRPC）的益处仍然未知。这项研究旨在确定新辅助CT对BRPC患者的益处。通过搜索1966年至2015年的数据库（PubMed，Embase和Cochrane图书馆），分析了所有前瞻性研究，其中对BRPC患者进行了术前新辅助CT或放化疗。剖腹手术和切除率是主要结果。次要结果是治疗引起的毒性，肿瘤反应和总生存期。数据显示为加权频率，置信区间为95％。总共进行了15项研究，共356例患者。所有患者均患有BRPC并接受了新辅助CT检查。术前治疗后，可切除的患者中有78.1％接受了剖腹手术，可切除的患者中有76.3％接受了剖腹手术。同样，有86％的标本被认为是显微镜阴性（R0）切除切缘。在治疗后重新分期时，完全/部分反应的加权频率为23.0％，稳定疾病为54.3％，进行性疾病为23.4％，与治疗相关的3-4级毒性反应为23.6％。切除患者的平均总生存时间为21.8个月，未切除患者的平均生存时间为11.6个月。这项荟萃分析表明，术前新辅助CT的好处是可以在BCT治疗期间使进展期疾病的BRPC患者免除手术。但是治疗后病变的降级并不常见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号